3 Top Canadian Cannabis Stocks to Watch This Month

Aphria (TSX:APHA)(NYSE:APHA) will release quarterly results this month, two more Canadian marijuana names have upcoming news this January.

| More on:
Shopping card with boxes labelled REITs, ETFs, Bonds, Stocks

Image source: Getty Images.

Investors in Canadian marijuana stocks are looking forward to the first industry earnings release of 2020 from Aphria (TSX:APHA)(NYSE:APHA) and two other local players expected to report this month.

Here’s what’s to watch on each report and why.

Aphria

Aphria stock rose over 22% in a day after an earnings beat in October last year, and the company is expected to report quarterly earnings again this month. Could the share price soar again?

The company will release its second-quarter fiscal 2020 results on January 14, before markets open. Results will cover the three-month period to November 30, 2019, which won’t be meaningfully comparable to 2018 figures on a year-over-year basis, as the 2018 comparable quarter enjoyed only a month-and-a-half of recreational pot sales, while the company later acquired a European pharmaceuticals distributor that’s contributing the bulk of sales revenue today.

This will be the first financial report from a major cannabis industry player in 2020, and investors will appreciate the numbers if the company could pull a third consecutive quarter of profitability growth.

Management gave an ambitious financial outlook for the fiscal year, when annual revenue is expected at $650-700 million and adjusted EBITDA to fall in the range of between $88 million and $90 million.

Given a $126 million top line and just one million in adjusted EBITDA during the first quarter, some significant growth is required to meet the reiterated guidance.

Analysts expect second-quarter sales to reach $130 million, with a high estimate of $137.7 million. The average estimate for the full fiscal year revenue stands at $591 million.

I hope there won’t a withdrawal of the prior guidance similar to what happened at a currently not-so-great-performing HEXO last year. I will be watching the margins too after first quarter cannabis adjusted gross margins sequentially shrank to 49.8% from 53% in a previous quarter.

Organigram Holdings

Low cost marijuana producer Organigram Holdings (TSX:OGI)(NASDAQ:OGI) will release its fiscal first quarter 2020 results on January 14, after market close. Like Aphria, the report will cover the quarter ending November 30 last year.

The company reported fourth-quarter revenues of $16.3 million, which were 34% lower sequentially and a sorry 5% adjusted gross margin due to provisions for sales returns, price adjustments and well as inventory and biological asset write-downs. However, management expected an improved first quarter outlook with higher net revenue and adjusted gross margins and lower selling, general and administrative expenses as a percentage of revenue.

Investors may therefore expect better results this month. Analysts’ predictions are for $16.1 million in net sales, but there’s a wide variance in the forecasts, with the most pessimistic sales estimates at $12.66 million, while optimistic estimates predict $21.11 million net revenue for the quarter.

Witnessing Organigram return to a solid growth trajectory could be reassuring for growth investors. If the company could maintain its enviously low production cost structure where cash costs per gram and “all-in” cultivation costs were reported at $0.66 and $0.94 per gram, respectively, during the most recently reported quarter, then I could be a long-term buyer at these low share price levels.

The other Canadian pot stock expected to report this month is retail giant Meta Growth Corp (TSXV:META) (formerly National Access Cannabis Corp), which has to fight fired-up competitors like Alcanna and Fire & Flower Holdings to maintain its lead among retail distributors.

United States focused cannabis play Liberty Health Sciences could give us another set of quarterly results later this month too.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends HEXO., HEXO., OrganiGram Holdings, and OrganiGram Holdings.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »